Leerink Partnrs Estimates Xeris Biopharma FY2025 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Equities researchers at Leerink Partnrs issued their FY2025 earnings estimates for Xeris Biopharma in a report released on Wednesday, June 4th. Leerink Partnrs analyst R. Ruiz expects that the company will post earnings per share of ($0.05) for the year. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share. Leerink Partnrs also issued estimates for Xeris Biopharma's FY2026 earnings at $0.10 EPS and FY2027 earnings at $0.30 EPS.

XERS has been the topic of a number of other reports. Wall Street Zen cut Xeris Biopharma from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Craig Hallum lifted their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $6.25.

Xeris Biopharma Price Performance

Shares of XERS opened at $4.58 on Monday. The business's fifty day moving average price is $4.56 and its 200 day moving average price is $4.09. Xeris Biopharma has a 12-month low of $2.03 and a 12-month high of $6.07. The stock has a market capitalization of $716.24 million, a PE ratio of -10.18 and a beta of 0.71.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million during the quarter, compared to analyst estimates of $57.61 million.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the sale, the insider now owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. This represents a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.47% of the company's stock.

Institutional Trading of Xeris Biopharma

Several large investors have recently made changes to their positions in XERS. Nuveen LLC acquired a new position in shares of Xeris Biopharma during the first quarter valued at $12,240,000. Parkman Healthcare Partners LLC lifted its stake in shares of Xeris Biopharma by 207.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,780,454 shares of the company's stock valued at $9,775,000 after acquiring an additional 1,201,943 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Xeris Biopharma by 75.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the period. Invesco Ltd. lifted its stake in shares of Xeris Biopharma by 1,387.8% during the first quarter. Invesco Ltd. now owns 1,026,838 shares of the company's stock valued at $5,637,000 after acquiring an additional 957,822 shares during the period. Finally, Driehaus Capital Management LLC lifted its stake in shares of Xeris Biopharma by 137.6% during the first quarter. Driehaus Capital Management LLC now owns 1,411,540 shares of the company's stock valued at $7,749,000 after acquiring an additional 817,525 shares during the period. Institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.